Propel Bio Management LLC Makes New $434,000 Investment in Compass Therapeutics, Inc. $CMPX

Key Points

• Propel Bio Management LLC has acquired a new position in Compass Therapeutics, purchasing 228,317 shares valued at approximately $434,000.
• Compass Therapeutics has received new price targets from analysts, with D. Boral Capital setting a target of $32.00 and Guggenheim increasing their target to $12.00.
• The stock has shown significant price movement, opening at $3.49 with a 1-year low of $1.25 and a high of $4.08, and presently holds an average rating of "Buy" among analysts.

Propel Bio Management LLC acquired a new position in Compass Therapeutics, Inc. (NASDAQ:CMPX - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 228,317 shares of the company's stock, valued at approximately $434,000. Compass Therapeutics comprises 0.5% of Propel Bio Management LLC's investment portfolio, making the stock its 15th biggest holding. Propel Bio Management LLC owned 0.17% of Compass Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of Compass Therapeutics by 298.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company's stock worth $25,000 after purchasing an additional 12,917 shares during the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $27,000. Mariner LLC purchased a new stake in shares of Compass Therapeutics in the fourth quarter worth approximately $30,000. Squarepoint Ops LLC bought a new position in shares of Compass Therapeutics in the fourth quarter valued at approximately $35,000. Finally, ProShare Advisors LLC grew its holdings in shares of Compass Therapeutics by 49.0% in the fourth quarter. ProShare Advisors LLC now owns 28,722 shares of the company's stock valued at $42,000 after acquiring an additional 9,451 shares in the last quarter. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Price Performance

NASDAQ CMPX traded up $0.07 during mid-day trading on Friday, reaching $3.44. The stock had a trading volume of 247,776 shares, compared to its average volume of 1,380,942. The stock has a market cap of $476.24 million, a PE ratio of -7.70 and a beta of 1.50. The company has a fifty day moving average price of $3.00 and a 200 day moving average price of $2.48. Compass Therapeutics, Inc. has a 1 year low of $1.27 and a 1 year high of $4.08.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). As a group, equities research analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CMPX has been the subject of several research reports. D. Boral Capital reissued a "buy" rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday, August 12th. Raymond James Financial upgraded Compass Therapeutics to an "outperform" rating and set a $9.00 price target on the stock in a research report on Tuesday, July 1st. Finally, Guggenheim lifted their price objective on Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating and nine have issued a Buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $12.89.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.